In a 18-month randomized, open-label, active-controlled phase III clinical trial (ATTRACT study, NCT00925301), a total of 57 adult patients with FD who had previously received ERT for ≥12 months were enrolled and randomly assigned in a 1.5:1 ratio to the oral drug migalastat group (n = 36, 150 mg once every other day) or to continue the original ERT regimen group (n = 21, agalsidase alfa 0.2 mg/kg or agalsidase beta 1.0 mg/kg, once every two weeks). Here, GLA is linked to Fabry disease.